Osteoarthritis Drug Development: ‘Clinically Meaningful Endpoints’ Remain Elusive

The landscape looks bleak for development of osteoarthritis drugs that can modify the underlying disease and slow its progression. But the US Food and Drug Administration, drug sponsors and academics are striving to overcome the area's unique challenges, which include identifying meaningful clinical endpoints.

Stakeholders delved into the topic at an all-day workshop convened by the FDA and the Arthritis Foundation in June